ALDX — Aldeyra Therapeutics, Inc. Stock Price, Chart & AI Report

Negative May 15, 2025 • 01:00 UTC GlobeNewswire Inc. • N/A

Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Organon, Aldeyra, Landstar, and ICU Medical due to issues related to financial results, regulatory matters, and accounting fraud.

OGN ALDX LSTR ICUI Organon Aldeyra Landstar ICU Medical

Sentiment note

Aldeyra received a Complete Response Letter from the FDA for its dry eye disease drug candidate, stating that the NDA failed to demonstrate efficacy in adequate and well-controlled studies.

Negative May 3, 2025 • 11:18 UTC GlobeNewswire Inc. • N/A

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

Aldeyra Therapeutics, a biotechnology company, is being investigated for potential securities law violations related to the failure of its Phase III dry eye disease drug trial. The company's stock price declined significantly after the FDA issued a Complete Response Letter citing concerns with the trial data.

ALDX Aldeyra Therapeutics dry eye disease securities violations FDA

Sentiment note

The article indicates that Aldeyra Therapeutics is being investigated for potential securities law violations related to the failure of its Phase III dry eye disease drug trial, which caused a significant decline in the company's stock price.

Negative Apr 29, 2025 • 01:00 UTC GlobeNewswire Inc. • N/A

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential securities law violations by TechTarget and Aldeyra Therapeutics. TechTarget disclosed errors in its financial statements and a potential goodwill impairment charge, while Aldeyra received a Complete Response Letter from the FDA for its dry eye disease treatment.

TTGT ALDX TechTarget Aldeyra Therapeutics securities law violations financial restatement goodwill impairment FDA Complete Response Letter

Sentiment note

The article states that Aldeyra Therapeutics received a Complete Response Letter from the FDA for its dry eye disease treatment, indicating that the FDA did not approve the treatment, which caused a sharp decline in the company's stock price.

Negative Apr 27, 2025 • 12:20 UTC GlobeNewswire Inc. • N/A

ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law

Aldeyra Therapeutics (ALDX) is being investigated for potential violations of federal securities laws after its Phase III dry eye disease trial failed to demonstrate the efficacy of its lead drug candidate, reproxalap, causing a 75% stock drop.

ALDX VTRS RH Aldeyra Therapeutics dry eye disease reproxalap securities investigation

Sentiment note

The company's Phase III trial for its lead drug candidate, reproxalap, failed to demonstrate efficacy in treating dry eye disease, leading to a 75% stock drop and a securities investigation.

Negative Apr 25, 2025 • 16:57 UTC GlobeNewswire Inc. • N/A

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

Aldeyra Therapeutics, Inc. received a Complete Response Letter from the FDA for its dry eye disease drug candidate, stating that the NDA failed to demonstrate efficacy in adequate and well-controlled studies. This led to a significant drop in the company's stock price.

ALDX Aldeyra Therapeutics dry eye disease FDA Complete Response Letter NDA

Sentiment note

The company received a Complete Response Letter from the FDA for its dry eye disease drug candidate, indicating that the NDA failed to demonstrate efficacy, which resulted in a significant drop in the stock price.

Neutral Apr 25, 2025 • 16:55 UTC GlobeNewswire Inc. • N/A

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Open Lending Corp. - LPRO

Pomerantz LLP is investigating claims on behalf of investors of Open Lending Corp. (LPRO) due to the company's delay in filing its annual report and larger-than-expected Q4 2024 net loss.

LPRO NOC ALDX Open Lending Corp. Northrop Grumman Corporation Aldeyra Therapeutics, Inc.

Sentiment note

The article mentions an investigation on behalf of Aldeyra Therapeutics investors, but does not provide any details about the company's performance or issues.

Negative Apr 24, 2025 • 17:57 UTC GlobeNewswire Inc. • Hagens Berman

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA’s Reproxalap Complete Response Letter – Hagens Berman

Aldeyra Therapeutics, Inc. (ALDX) received a Complete Response Letter from the FDA for its drug candidate reproxalap, causing a 70% drop in its stock price. Hagens Berman is investigating potential securities law violations related to Aldeyra's statements about the drug's approval prospects.

ALDX Aldeyra Therapeutics FDA reproxalap dry eye disease securities law violations

Sentiment note

The company received a Complete Response Letter from the FDA for its drug candidate reproxalap, which contradicted its previous assurances of imminent approval. This led to a 70% drop in the stock price, wiping out over $200 million in shareholder value.

Negative Apr 22, 2025 • 01:00 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against TechTarget and Aldeyra Therapeutics due to financial restatements and a complete response letter from the FDA, respectively.

TTGT ALDX TechTarget Aldeyra Therapeutics financial restatements FDA complete response letter

Sentiment note

Aldeyra Therapeutics received a Complete Response Letter from the FDA stating that the NDA for reproxalap failed to demonstrate efficacy in treating dry eye disease, leading to a sharp decline in the company's stock price.

Negative Apr 19, 2025 • 12:06 UTC GlobeNewswire Inc. • Bfa Law

ALDX INVESTOR NEWS: Aldeyra Therapeutics, Inc. Investors may be able to Recover Losses in Class Action Investigation -- Contact BFA Law (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc. announced the success of its Phase III dry eye chamber clinical trial for reproxalap, but the trial data suffered from potential methodological issues and failed to demonstrate reproxalap's efficacy, leading to a stock price decline of nearly 75% when the FDA issued a Complete Response Letter.

ALDX Aldeyra Therapeutics dry eye disease reproxalap FDA clinical trial

Sentiment note

The article indicates that Aldeyra Therapeutics' Phase III trial for its lead drug candidate reproxalap failed to demonstrate efficacy in treating dry eye disease, leading to a significant stock price decline when the FDA issued a Complete Response Letter.

Negative Apr 18, 2025 • 18:52 UTC GlobeNewswire Inc. • Hagens Berman

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA’s Reproxalap Complete Response Letter – Hagens Berman

Aldeyra Therapeutics, Inc. (ALDX) received a Complete Response Letter from the FDA for its drug candidate reproxalap, causing a 70% drop in its stock price. Hagens Berman is investigating potential securities law violations related to Aldeyra's statements about the drug's approval prospects.

ALDX Aldeyra Therapeutics FDA reproxalap dry eye disease securities law violations

Sentiment note

The company received a Complete Response Letter from the FDA for its drug candidate reproxalap, which contradicted its previous assurances of imminent approval, leading to a 70% drop in its stock price and a loss of over $200 million in market capitalization. This has prompted an investigation by Hagens Berman into potential securities law violations related to the company's statements about the drug's approval prospects.

Negative Apr 16, 2025 • 01:00 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against TechTarget and Aldeyra Therapeutics due to financial restatements and a complete response letter from the FDA, respectively.

TTGT ALDX TechTarget Aldeyra Therapeutics financial restatements FDA complete response letter

Sentiment note

Aldeyra Therapeutics received a Complete Response Letter from the FDA stating that the NDA for reproxalap failed to demonstrate efficacy in treating dry eye disease, leading to a sharp decline in the company's stock price.

Negative Apr 11, 2025 • 11:43 UTC GlobeNewswire Inc. • N/A

ALDX STOCK NOTIFICATION: Did Aldeyra Therapeutics, Inc. Violate the Securities Laws? Investors are Notified to Contact BFA Law (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc. is being investigated for potential securities law violations related to the failure of its Phase III dry eye chamber clinical trial for its lead drug candidate reproxalap. The company's claims about the trial's success and the drug's efficacy were allegedly misleading, leading to a significant stock price decline when the truth was revealed.

ALDX Aldeyra Therapeutics securities fraud dry eye disease reproxalap

Sentiment note

The article indicates that Aldeyra Therapeutics is being investigated for potential securities law violations related to misleading claims about the success and efficacy of its Phase III clinical trial for reproxalap, leading to a significant stock price decline when the truth was revealed.